He envisions a future in which a patient’s BMI, dietary habits, and exercise commitments, along with their single cell spatial metabolomic atlas of disease progression, will be analyzed all together to find optimum therapies that can work with biologics and metabolic boosting regimens, potentially increasing the survival of cancers, women’s diseases, and metabolic disorders.
“We will have opportunities to talk about spatial single cell metabolomic medicine, to stratify patients and design next-generation combination therapies with an integrated view of genes and chemical activity roadmaps, for more efficient management of cancer and other diseases,” Coskun said.
In creating their scSpaMet framework, the researchers must integrate expensive machines that live in the worlds of nanotechnology and chemistry right now. The system will require clinical-friendly optimizations to be able to run single cell metabolic imaging measurements in healthcare settings. Coskun expects the cost and user-friendliness will be improved in the near future to reach the bedside.
“When researchers achieved single cell sequencing, it was a revolutionary moment in medicine,” Coskun said. “Now, we believe single cell spatial metabolic profiling will push the medical practice into new heights.”
This research was supported by the Burroughs Wellcome Fund, and the Bernie Marcus Early Career Professorship, as well as the National Science Foundation (Grant ECCS-1542174), (Grant ECCS-2-25462), American Cancer Society, and National Institutes of Health grants (R21AG081715, R21AI173900, and R35GM151028)
Citation: Thomas Hu, Mayar Allam, Shuangyi Cai, Walter Henderson, Brian Yueh, Aybuke Garipcan, Anton V. Ievlev, Maryam Afkarian, Semir Beyaz, and Ahmet F. Coskun. “Single-cell spatial metabolomics with cell-type specific protein profiling for tissue systems biology,” Nature Communications (Dec. 13, 2023)